New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
16:17 EDTCERUCerulean reports Q2 EPS (44c), consensus (36c)
Reports Q2 revenue $33K. As of June 30, Cerulean had cash and cash equivalents of $64.3M. Cerulean estimates that its current cash and cash equivalents will allow it to fund several ongoing single-arm clinical trials of CRLX101, an ongoing randomized Phase 2 clinical trial of CRLX101, and a planned Phase 1 trial of CRLX301. CEO Oliver Fetzer said, "We anticipate announcing data from two ongoing single-arm CRLX101 trials in the first quarter of 2015, data from an ongoing randomized CRLX101 trial by the end of 2015, and data from a planned Phase 1 CRLX301 trial by the end of 2015."
News For CERU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2015
07:03 EDTCERUCerulean, AstraZeneca partner to evaluate LYNPARZA, CRLX101 combo
Cerulean (CERU) announced that it has entered into a collaboration with AstraZeneca (AZN) and the National Cancer Institute, part of the National Institutes of Health, to study LYNPARZA and CRLX101. The collaboration will explore the synergistic effects of AstraZeneca's LYNPARZA, a poly ADP ribose polymerase inhibitor, and CRLX101, Cerulean's inhibitor of topoisomerase 1. The NCI will conduct a combination Phase I/IIa trial in the Branch led by Yves Pommier, M.D., Ph.D., Chief of the Developmental Therapeutics Branch.
November 16, 2015
16:58 EDTCERUCerulean provides update on expected clinical data publication
Subscribe for More Information
16:54 EDTCERUCerulean reports Q3 EPS (39c), consensus (41c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use